GNF6702

GNF6702
Identifiers
	IUPAC name N-[4-fluoro-3-(6-pyridin-2-yl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)phenyl]-2,4-dimethyl-1,3-oxazole-5-carboxamide;
CAS Number	1799329-72-8 ;
PubChem CID	91810392;
ChemSpider	58827646;
ChEBI	CHEBI:133824 ;
Chemical and physical data
Formula	C22H16FN7O3
Molar mass	429.406 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES n5ccccc5-c(cn1n4)cnc1nc4-c3cc(ccc3F)NC(=O)c2oc(C)nc2C;
	InChI InChI=1S/C22H16FN7O2/c1-12-19(32-13(2)26-12)21(31)27-15-6-7-17(23)16(9-15)20-28-22-25-10-14(11-30(22)29-20)18-5-3-4-8-24-18/h3-11H,1-2H3,(H,27,31); Key:WXZFCGRYVWYYTG-UHFFFAOYSA-N;

GNF6702 is the name for a broad-spectrum antiprotozoal drug invented by researchers working at the Genomics Institute of the Novartis Research Foundation in 2013,[1] with activity against leishmaniasis, Chagas disease and sleeping sickness. These three diseases are caused by related kinetoplastid parasites, which share similar biology. GNF6702 acts as allosteric proteasome inhibitor which was effective against infection with any of the three protozoal diseases in mice, while having little evident toxicity to mammalian cells.[2]

References

Biggart A, et al. Compounds and compositions for the treatment of parasitic diseases. US20150175613, priority date Dec 19, 2013
Khare S, et al. Proteasome inhibition for treatment of leishmaniasis, Chagas disease and sleeping sickness. Nature 2016 doi:10.1038/nature19339

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[1] Biggart A, et al. Compounds and compositions for the treatment of parasitic diseases. US20150175613, priority date Dec 19, 2013

[2] Khare S, et al. Proteasome inhibition for treatment of leishmaniasis, Chagas disease and sleeping sickness. Nature 2016 doi:10.1038/nature19339

GNF6702

See also

References